Neuroendocrine Carcinoma Market Size, Share & Trends Analysis Report By Site (Gastrointestinal, Lung, Brain, Pancreatic), By Diagnostic Tools (Imaging, Biopsy, Serology), By Treatment Type (Somatostatin Analogs, Targeted Therapy, Chemotherapy), By End User (Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers), By Stage (Localized, Regional, Distant), By Grade (Low, Intermediate, High) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Neuroendocrine Carcinoma Market Size

The global neuroendocrine carcinoma market size was valued at USD 2.12 billion in 2025 and is projected to grow from USD 2.29 billion in 2026 to USD 4.22 billion by 2034, registering a CAGR of 7.96% during the forecast period from 2026 to 2034. North America dominated the neuroendocrine carcinoma market with a market share of 39.5% in 2025.

Cancers that originate in specialized cells known as neuroendocrine cells might be referred to as neuroendocrine tumors. These cells have characteristics that are equivalent to those of nerve cells and cells that produce hormones. These tumors are able to develop in any part of the body. This illness can be deadly if it is not caught and treated in its early stages. Therefore, getting an accurate diagnosis as soon as possible and beginning therapy as soon as possible are both extremely important factors that need to be taken into account. There are a lot of companies competing in the market for neuroendocrine carcinoma, and a lot of those companies are trying to produce goods and methods that can assist in the early identification of neuroendocrine carcinoma. Due to this, the market for neuroendocrine carcinoma may have growth that is encouraging in the future.

Site Insights

As of right now, the part that represents the stomach has the largest proportion, followed by the segment that represents the lungs. Within the therapeutic treatment, category are subcategories such as chemotherapy, radiation therapy, and surgical procedures. In addition, the surgical procedure is subdivided into radiofrequency ablation (RFA), as well as local excision. Since it was discovered that radiofrequency ablation is the only treatment that may cure pancreatic NETs, it is anticipated that the market for this treatment would experience a significant increase. On the other hand, complications that may arise as a result of the procedure, such as pancreatic fistula, haemorrhage, and the spread of tumours, are likely to slow down its acceptance over the next several years. Excision at the local level is typically performed for kidney malignancies. Chemotherapy was shown to be the most effective treatment option for pancreatic NETs; however, there has not yet been a therapeutic option discovered that is effective in curing carcinoid tumours. When dealing with tumours that are developing slowly, it is often necessary to combine chemotherapy with surgical removal.

Request Customizationto receive a tailored report.

Treatment Type Insights

It is anticipated that the persistent efforts that pharmaceutical firms are making in order to create tailored medicine will increase demand. The medications streptozocin (Zanosar) and 5-fluorouracil (5-FU, Adrucil) are the ones that are utilized the most frequently in the treatment of neuroendocrine carcinomas. Targeted therapy has been gaining traction as a viable option for the treatment of this specific kind of cancer in recent years. For example, Everolimus (Afinitor) by Novartis and Sunitinib (Sutent) by Pfizer are two significant medications that are utilized for targeted therapy. Both companies manufacture these drugs. Drugs like these are employed in the treatment of renal cell carcinomas. Some of the compounds that are currently in the development stage for the treatment of NETs are Avastin, Atiprimod, and Lutathera.

Diagnostic Tools Insights

The diagnostic instruments used in imaging, biopsy, serology, and other areas are taken into consideration while dividing up the market. The field of serology is broken down even further into subfields such as blood tests, urine tests, and molecular tests, among others. The imaging market may be further broken down into sub-markets such as CT scan, X-ray, PET scan, and others. The rising usage of improved diagnostic imaging methods that may identify extremely tiny malignant tumours that are clinically inconsequential is contributing to the rise of the imaging sector throughout the forecast period. This increase is expected to occur in the coming years.

Speak to an Analystto discuss market opportunities.

Regional Insights

It's generally agreed that the most lucrative market in North America. Because of the rising prevalence of NETs in the United States, this continent has become the top target for investment and the introduction of new products. Due to the vast patient population in this region, the United States is in top place internationally in terms of the number of clinical trials being conducted for NETs, followed by the United Kingdom. The National Health Service reported in 2015 that roughly 8,000 persons in the United Kingdom are diagnosed with a carcinoid tumour each and every year, and it is anticipated that this figure will continue to rise throughout the course of the projected period. This demonstrates the potential growth in demand for treatments for NETs in Europe over the next few years. Due to the rising prevalence of neuroendocrine tumours in Asia and the Pacific, the market for neuroendocrine carcinoma is expected to see profitable expansion in the coming years.

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in Neuroendocrine Carcinoma Market